Antibodies Archives

News and Trends 14 Mar 2015

Samsung Bioepis Submits a Biosimilar Candidate, to the European Medicines Agency

Samsung Bioepis announced their submission to the to the European Medicines Agency (EMA) for SB2, its Remicade (Infliximab) biosimilar candidate. This is the second biosimilar candidate Marketing Authorization Application (MAA) that Samsung Bioepis has submitted to the EMA. The MAA is based on results from an extensive head-to-head preclinical data package comparing SB2 to the originator, a […]

March 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 Mar 2015

First Treatment Approved under Early Access to Medicine Scheme (EAMS)

Today, it has been accepted! The first drug approved through the Early Access to Medicine Scheme (EAMS), named pembrolizumab, is an immunotherapy treatment for advanced melanoma. The treatment has been developed by Merck, known as MSD outside the United States and Canada, with early development work carried out using MRC Technology’s antibody humanization expertise. EAMS is […]

March 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 23 Feb 2015

Adimab, the secret weapon of the Big Pharma companies

After establishing discovery collaborations with over 30 companies during the past five years (Roche, Pfizer, Genentech, Novartis, Merck, Lilly, Celgene, Novo Nordisk and GSK), it is today with Sanofi that the biotech company Adimab enters into partnership for the development of bispecific antibodies. Adimab integrated antibody discovery and optimization platform, offers unprecedent speed to purify […]

February 23, 2015 - 2 minutesmins - By Cédric Brock

News and Trends 16 Dec 2014

An Effective Renewed Partnership for Treatment of Gynecological Cancers

Curie-Cancer, the part responsible for developing Institut Curie’s industry partnership activities, and GamaMabs Pharma, a company specialized in the development of monoclonal antibodies for cancer, extended their partnership to develop the 3C23K antibody for the treatment of gynecological cancers. An initial partnership agreement was concluded in 2013 and the results of work on the 3C23K antibody were presented to the Ovarian […]

December 16, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 30 Oct 2014

Review : Ebola, The True Story

The first outbreaks of Ebola (also known as Ebola haemorrhagic fever) have occurred in isolated villages in central Africa, near tropical forests, but the recent outbreak in West Africa has affected major urban centers as well as rural areas. The Ebola virus disease shows an average fatality rate about 50%. In previous outbreaks, the rate […]

October 30, 2014 - 26 minutesmins - By Cédric Brock

News and Trends 3 Oct 2014

A new way to develop therapeutic monoclonal antibodies against Cancer

Up to now, a vast majority of antibodies targets proteins. Why not targeting something else? ImmuSmol, a start-up based in Bordeaux South of France is developing monoclonal antibodies against small molecules involved in tumor immune escape. This French start-up has just raised €500k to complete its preclinical proof-of-concept. Bordeaux is one of the biggest wine […]

October 3, 2014 - 2 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us